Sharen schreef op 27 september 2020 20:45:
De amerikaanse arts, dr Bernstein, heeft recent de resultaten gepubliceerd van het gebruik van subcutane C1-esterase remmer bij 65-plus patienten met HAE.
Omdat Bernstein ook de arts is die de US-trial zal doen met Ruconest bij Covid vermoed ik dat het bij dit artikel ook om Ruconest gaat.
Resultaten (zie ‘vet’ onderin) waren dus prima.
Artikel staat op:
pubmed.ncbi.nlm.nih.gov/32445670/———
Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedemaJonathan A Bernstein et al. Ann Allergy Asthma Immunol. 2020 Sep.
Abstract
Background: Patients aged 65 years and older with hereditary angioedema (HAE) owing to C1-inhibitor (C1-INH) deficiency may have an altered response to treatment and are at higher risk for treatment-related adverse events (AEs) because of comorbidities and polypharmacy.
Objective: To investigate the safety and efficacy of subcutaneous C1 esterase inhibitor (C1-INH) in patients aged 65 years and older treated in an open-label extension of a phase 3 trial.
Methods: Eligible patients (=4 attacks for more than 2 consecutive months) were randomized to receive twice-weekly subcutaneous C1-INH with a dosage of 40 IU/kg or 60 IU/kg for 52 to 140 weeks. Safety end points and efficacy outcomes were evaluated for patients aged 65 years and above and younger than 65 years.
Results: Of the 126 patients treated, 10 were 65 years and older (mean age [range], 68 [65-72 years]). A total of 8 of 10 patients had multiple comorbidities, and 6 of these 10 patients were taking more than 5 non-HAE-related drugs concomitantly. AEs occurring in more than 1 patient included injection site bruising (n = 2, related), injection site pain (n = 2, related), urinary tract infection (n = 2, unrelated), and diarrhea (n = 2, unrelated). No thromboembolic events or cases of anaphylaxis were reported. Two patients aged 65 years and older experienced unrelated serious AEs (dehydration and hypokalemia in 1 and pneumonia and an HAE attack leading to hospitalization in another). A total of 6 of 9 evaluable patients were responders, with a greater than or equal to 50% reduction in HAE attacks vs prestudy; 6 of 10 patients had less than 1 attack over 4 weeks and 3 were attack-free (median attack rate, 0.52 attacks per month).
Conclusion: Subcutaneous C1-INH was well-tolerated and effective in the management of HAE in patients aged 65 years and older with multiple comorbid conditions and polypharmacy.